載入中
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
前收盤價
US$1.41
−US$0.03 · -2.08%
盤中時間採用ET。市場資料可能有所延遲。
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
日內區間
目前US$1.41
52週區間
目前US$1.41
盤中時間採用ET。市場資料可能有所延遲。
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
日內區間
目前US$1.41
52週區間
目前US$1.41
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 4109.5萬 USD | 3608.4萬 USD | 1575.9萬 USD | — |
| 銷貨成本 | 11.6萬 USD | — | — | — | — |
| 毛利 | −11.6萬 USD | 4109.5萬 USD | 3608.4萬 USD | 1575.9萬 USD | — |
| 研究與開發 | 1284.3萬 USD | 3742.8萬 USD | 3703.9萬 USD | 3754.7萬 USD | 2637.9萬 USD |
| 銷售、一般及管理費用 | 1079.1萬 USD | 1193.6萬 USD | 1356.7萬 USD | 1723.9萬 USD | 1140.7萬 USD |
| 營業費用 | 2363.4萬 USD | 4936.4萬 USD | 5060.6萬 USD | 7783.5萬 USD | 3778.6萬 USD |
| 利息收入 | 83.3萬 USD | 138.1萬 USD | 233.4萬 USD | 42萬 USD | 5.7萬 USD |
| 利息支出 | — | — | 49.1萬 USD | 105.3萬 USD | 107.3萬 USD |
| 折舊和攤銷 | 11.6萬 USD | 13.7萬 USD | 12.6萬 USD | 11.8萬 USD | 7.2萬 USD |
| 營業利益 | −2363.4萬 USD | −826.9萬 USD | −1452.2萬 USD | −6207.6萬 USD | −3778.6萬 USD |
| 淨利 | −2239.8萬 USD | −806.7萬 USD | −1333.5萬 USD | −6242.8萬 USD | −3898萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.25
上漲空間 343.26%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI318.24萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF84.75萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC21.02萬0.02%13.17億 USD0.60%US$183+0.11%
Avantis U.S. Small Cap Equity ETFAVSC10.86萬—30.82億 USD0.25%US$69.98+0.03%
Invesco NASDAQ Future Gen 200 ETFQQQS7.41萬0.33%2275.83萬 USD0.20%US$42.145+1.39%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
